This article is more than 5 years old. Information may no longer be current.
Patient outcomes affected by chemotherapy-associated bowel syndrome, neutropenia
Click Here to Manage Email Alerts
Chemotherapy-associated bowel syndrome had a significant effect on outcome in patients with chemotherapy-associated neutropenia, according to research presented at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy.
In a multicenter study, researchers assessed a clinical rule to detect patients at risk for severe abdominal complications early on during chemotherapy-associated neutropenia. To be included in the study, patients had to experience neutropenia for at least 5 consecutive days. A combination of fever and abdominal pain, or lack of bowel movement for 72 or more hours defined chemotherapy-associated bowel syndrome (CABS), according to the study. Researchers assessed risk factors for transfer to intensive care and death by backward-stepwise binary logistic regression analyses.
Overall, 359 patients experienced 521 neutropenic episodes, with a 35% incidence (n=126) in patients experiencing CABS first episodes. Eleven percent of patients were transferred to intensive care and 5% of patients died in first episodes. Risk factors for transfer to intensive care were identified as CABS (OR=4.735; 95% CI, 2.297-9.833) and duration of neutropenia (OR=1.061/day; 95% CI, 1.021-1.103), whereas CABS (OR=4.611; 95% CI, 1.573-13.515) and mitoxantrone administration (OR=3.628; 95% CI, 1.169-11.256) were identified as risk factors for death, according to the study.
For more information:
- Vehreschild MJ. #1124. Presented at: 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 17-20; Chicago.
Disclosure: Dr. Vehreschild reports no relevant financial disclosures.
 |
Follow HemOncToday.com on Twitter. |